Rémi Letestu

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Andy C. Rawstron, Claudia Fazi, Andreas Agathangelidis et al. · Leukemia · 2015 · 241 citations · Full text

Medicine, Hematology, Oncology +17

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

Andy C. Rawstron, Sebastian Böttcher, Rémi Letestu et al. · Leukemia · 2012 · 205 citations

Medicine, Hematology, Oncology +15

Rituximab for Patients With Refractory Mucous Membrane Pemphigoid

C. Le Roux‐Villet, C. Prost‐Squarcioni, M. Alexandre et al. · Archives of Dermatology · 2011 · 146 citations · Full text

Medicine, Immunology, Pharmacotherapy +9

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Anne Quinquenel, Luc‐Matthieu Fornecker, Rémi Letestu et al. · Blood · 2019 · 129 citations · Full text

Life Sciences, Genetics, Hematology +10

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé et al. · Blood Advances · 2019 · 121 citations · Full text

Medicine, Hematology, Oncology +17